Systematic review: Non-invasive methods of fibrosis analysis in chronic hepatitis C

Alimentary Pharmacology and Therapeutics

Volumn 30, Issue 6, 2009, Pages 557-576

  Smith, J O ^a   Sterling, R K ^a,b  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 ACETANISIDINE; ALANINE AMINOTRANSFERASE; ALBUMIN; ALPHA 2 MACROGLOBULIN; APOLIPOPROTEIN A1; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; C REACTIVE PROTEIN; CARBON 13; CASPASE; COLLAGEN TYPE 1; COLLAGEN TYPE 2; COLLAGEN TYPE 3; COLLAGEN TYPE 4; DEETHYLLIDOCAINE; FERRITIN; GAMMA GLUTAMYLTRANSFERASE; GELATINASE A; GELATINASE B; GLYCOSAMINOGLYCAN; HAPTOGLOBIN; HYALURONIC ACID; INTERSTITIAL COLLAGENASE; PHYTATE TC 99M; PROCOLLAGEN TYPE 3 AMINOPROPEPTIDE; PROTHROMBIN; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2; TRANSFERRIN; VIRUS RNA;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALBUMIN BLOOD LEVEL; ARTIFICIAL NEURAL NETWORK; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; BREATH ANALYSIS; COLLAGEN DEGRADATION; COLLAGEN SYNTHESIS; ECHOGRAPHY; ELASTOGRAPHY; EMBASE; EXTRACELLULAR MATRIX; FERRITIN BLOOD LEVEL; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; GLYCOSYLATION; HEPATITIS C; HISTOLOGY; HUMAN; INTERMETHOD COMPARISON; LIVER; LIVER BIOPSY; LIVER CYTOSOL; LIVER FIBROSIS; LIVER FUNCTION; LIVER METABOLISM; LIVER MICROSOME; LIVER MITOCHONDRION; MEAN CORPUSCULAR VOLUME; MEDICAL INFORMATION; MEDLINE; NON INVASIVE PROCEDURE; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PRIORITY JOURNAL; PROTEOMICS; PROTHROMBIN TIME; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SYSTEMATIC REVIEW; THROMBOCYTE COUNT; TRANSFERRIN BLOOD LEVEL;

AGE FACTORS; BIOLOGICAL MARKERS; DIAGNOSTIC IMAGING; DIAGNOSTIC TESTS, ROUTINE; HEPATITIS C, CHRONIC; HUMANS; LIVER; LIVER CIRRHOSIS; SEX FACTORS;

EID: 68949205020     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2009.04062.x     Document Type: Review

References (154)

1. Schlichting P, Fauerholdt L, Christensen E, Poulsen H, Juhl E, Tygstrup N. Clinical relevance of restrictive morphological criteria for the diagnosis of cirrhosis in liver biopsies. Liver 1981 1 : 56 61.
2. Bravo AA, Sheth SG, Chopra S. Liver biopsy. N Engl J Med 2001 344 : 495 500.
3. Froehlich F, Lamy O, Fried M, Gonvers JJ. Practice and complications of liver biopsy. Results of a nationwide survey in Switzerland. Dig Dis Sci 1993 38 : 1480 4.
4. Thampanitchawong P, Piratvisuth T. Liver biopsy: complications and risk factors. World J Gastroenterol 1999 5 : 301 4.
5. Lindor KD, Bru C, Jorgensen RA, et al. The role of ultrasonography and automatic-needle biopsy in outpatient percutaneous liver biopsy. Hepatology 1996 23 : 1079 83.
6. Abdi W, Millan JC, Mezey E. Sampling variability on percutaneous liver biopsy. Arch Intern Med 1979 139 : 667 9.
7. Maharaj B, Bhoora IG. Complications associated with percutaneous needle biopsy of the liver when one, two or three specimens are taken. Postgrad Med J 1992 68 : 964 7.
8. Patel K, Gordon SC, Jacobson I, et al. Evaluation of a panel of non-invasive serum markers to differentiate mild from moderate-to-advanced liver fibrosis in chronic hepatitis C patients. J Hepatol 2004 41 : 935 42.
9. Kaul V, Friedenberg FK, Braitman LE, et al. Development and validation of a model to diagnose cirrhosis in patients with hepatitis C. Am J Gastroenterol 2002 97 : 2623 8.
10. Pohl A, Behling C, Oliver D, Kilani M, Monson P, Hassanein T. Serum aminotransferase levels and platelet counts as predictors of degree of fibrosis in chronic hepatitis C virus infection. Am J Gastroenterol 2001 96 : 3142 6.
11. Cheung RC, Currie S, Shen H, et al. Can we predict the degree of fibrosis in chronic hepatitis C patients using routine blood tests in our daily practice? J Clin Gastroenterol 2008 42 : 827 34.
12. Giannini EG, Zaman A, Ceppa P, Mastracci L, Risso D, Testa R. A simple approach to noninvasively identifying significant fibrosis in chronic hepatitis C patients in clinical practice. J Clin Gastroenterol 2006 40 : 521 7.
13. Boyacioǧlu S, Gür G, Yilmaz U, et al. Investigation of possible clinical and laboratory predictors of liver fibrosis in hemodialysis patients infected with hepatitis C virus. Transplant Proc 2004 36 : 50 2.
14. Fehr T, Riehle HM, Nigg L, et al. Evaluation of hepatitis B and hepatitis C virus-infected renal allograft recipients with liver biopsy and noninvasive parameters. Am J Kidney Dis 2003 42 : 193 201.
15. Benlloch S, Berenguer M, Prieto M, Rayón JM, Aguilera V, Berenguer J. Prediction of fibrosis in HCV-infected liver transplant recipients with a simple noninvasive index. Liver Transpl 2005 11 : 456 62.
16. Koda M, Matunaga Y, Kawakami M, Kishimoto Y, Suou T, Murawaki Y. FibroIndex, a practical index for predicting significant fibrosis in patients with chronic hepatitis C. Hepatology 2007 45 : 297 306.
17. Wai CT, Greenson JK, Fontana RJ, et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 2003 38 : 518 26.
18. Snyder N, Gajula L, Xiao SY, et al. APRI: an easy and validated predictor of hepatic fibrosis in chronic hepatitis C. J Clin Gastroenterol 2006 40 : 535 42.
19. Yu ML, Lin SM, Lee CM, et al. A simple noninvasive index for predicting long-term outcome of chronic hepatitis C after interferon-based therapy. Hepatology 2006 44 : 1086 97.
20. Snyder N, Nguyen A, Gajula L, et al. The APRI may be enhanced by the use of the FIBROSpect II in the estimation of fibrosis in chronic hepatitis C. Clin Chim Acta 2007 381 : 119 23.
21. Al-Mohri H, Cooper C, Murphy T, Klein MB. Validation of a simple model for predicting liver fibrosis in HIV/hepatitis C virus-coinfected patients. HIV medicine 2005 6 : 375 8.
22. Carvalho-Filho RJ, Schiavon LL, Narciso-Schiavon JL, et al. Optimized cutoffs improve performance of the aspartate aminotransferase to platelet ratio index for predicting significant liver fibrosis in human immunodeficiency virus/hepatitis C virus co-infection. Liver international 2008 28 : 486 93.
23. Shastry L, Wilson T, Lascher S, Nord JA. The utility of aspartate aminotransferase/platelet ratio index in HIV/hepatitis C-co-infected patients. AIDS 2007 21 : 2541 3.
24. Chrysanthos NV, Papatheodoridis GV, Savvas S, et al. Aspartate aminotransferase to platelet ratio index for fibrosis evaluation in chronic viral hepatitis. Eur J Gastroenterol Hepatol 2006 18 : 389 96.
25. Forns X, Ampurdanès S, Llovet JM, et al. Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model. Hepatology 2002 1 (4 Pt 1) 986 92.
26. Macías J, Girón-González JA, González-Serrano M, et al. Prediction of liver fibrosis in human immunodeficiency virus/hepatitis C virus coinfected patients by simple non-invasive indexes. Gut 2006 55 : 409 14.
27. Martínez-Bauer E, Crespo J, Romero-Gómez M, et al. Development and validation of two models for early prediction of response to therapy in genotype 1 chronic hepatitis C. Hepatology 2006 43 : 72 80.
28. Sterling RK, Lissen E, Clumeck N, et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology 2006 43 : 1317 25.
29. Vallet-Pichard A, Mallet V, Nalpas B, et al. FIB-4: an inexpensive and accurate marker of fibrosis in HCV infection. comparison with liver biopsy and fibrotest. Hepatology 2007 46 : 32 6.
30. Berenguer J, Bellón JM, Miralles P, et al. Identification of liver fibrosis in HIV/HCV-coinfected patients using a simple predictive model based on routine laboratory data. J Viral Hepat 2007 14 : 859 69.
31. Loko M-A, Castera L, Dabis F, et al. Validation and comparison of simple noninvasive indexes for predicting liver fibrosis in HIV-HCV-coinfected patients: ANRS CO3 Aquitaine cohort. Am J Gastroenterol 2008 103 : 1973 80.
32. Cacoub P, Carrat F, Bédossa P, et al. Comparison of non-invasive liver fibrosis biomarkers in HIV/HCV co-infected patients: the fibrovic study - ANRS HC02. J Hepatol 2008 48 : 765 73.
33. Jeffers LJ, Coelho-Little ME, Cheinquer H, et al. Procollagen-III peptide and chronic viral C hepatitis. The American journal of gastroenterology 1995 90 : 1437 40.
34. Serejo F, Costa A, Oliveira AG, Ramalho F, Batista A, De Moura MC. Alpha-interferon improves liver fibrosis in chronic hepatitis C: clinical significance of the serum N-terminal propeptide of procollagen type III. Dig Dis Sci 2001 46 : 1684 9.
35. Trocme C, Leroy V, Sturm N, et al. Longitudinal evaluation of a fibrosis index combining MMP-1 and PIIINP compared with MMP-9, TIMP-1 and hyaluronic acid in patients with chronic hepatitis C treated by interferon-alpha and ribavirin. J Viral Hepat 2006 13 : 643 51.
36. Walsh KM, Fletcher A, MacSween RN, Morris AJ. Comparison of assays for N-amino terminal propeptide of type III procollagen in chronic hepatitis C by using receiver operating characteristic analysis. Eur J Gastroenterol Hepatol 1999 11 : 827 31.
37. Walsh KM, Timms P, Campbell S, MacSween RN, Morris AJ. Plasma levels of matrix metalloproteinase-2 (MMP-2) and tissue inhibitors of metalloproteinases -1 and -2 (TIMP-1 and TIMP-2) as noninvasive markers of liver disease in chronic hepatitis C: comparison using ROC analysis. Dig Dis Sci 1999 44 : 624 30.
38. Larrousse M, Laguno M, Segarra M, et al. Noninvasive diagnosis of hepatic fibrosis in HIV/HCV-coinfected patients. J Acquir Immune Defic Syndr 2007 46 : 304 11.
39. Attallah AM, Toson EA, Shiha GE, Omran MM, Abdel-Aziz MM, El-Dosoky I. Evaluation of serum procollagen aminoterminal propeptide III, laminin, and hydroxyproline as predictors of severe fibrosis in patients with chronic hepatitis C. Journal of immunoassay & immunochemistry 2007 28 : 199 211.
40. Verbaan H, Bondeson L, Eriksson S. Non-invasive assessment of inflammatory activity and fibrosis (grade and stage) in chronic hepatitis C infection. Scand J Gastroenterol 1997 32 : 494 9.
41. Saitou Y, Shiraki K, Yamanaka Y, et al. Noninvasive estimation of liver fibrosis and response to interferon therapy by a serum fibrogenesis marker, YKL-40, in patients with HCV-associated liver disease. World J Gastroenterol 2005 11 : 476 81.
42. Schiavon LL, Narciso-Schiavon JL, Carvalho Filho RJ, et al. Serum levels of YKL-40 and hyaluronic acid as noninvasive markers of liver fibrosis in haemodialysis patients with chronic hepatitis C virus infection. J Viral Hepat 2008 15 : 666 74.
43. Guéchot J, Laudat A, Loria A, Serfaty L, Poupon R, Giboudeau J. Diagnostic accuracy of hyaluronan and type III procollagen amino-terminal peptide serum assays as markers of liver fibrosis in chronic viral hepatitis C evaluated by ROC curve analysis. Clin Chem 1996 42 : 558 63.
44. McHutchison JG, Blatt LM, de Medina M, et al. Measurement of serum hyaluronic acid in patients with chronic hepatitis C and its relationship to liver histology. Consensus Interferon Study Group. J Gastroenterol Hepatol 2000 15 : 945 51.
45. Mehta P, Ploutz-Snyder R, Nandi J, Rawlins SR, Sanderson SO, Levine RA. Diagnostic accuracy of serum hyaluronic acid, FIBROSpect II, and YKL-40 for discriminating fibrosis stages in chronic hepatitis C. The American journal of gastroenterology 2008 103 : 928 36.
46. Patel K, Lajoie A, Heaton S, et al. Clinical use of hyaluronic acid as a predictor of fibrosis change in hepatitis C. J Gastroenterol Hepatol 2003 18 : 253 7.
47. Yilmaz S, Bayan K, Tüzün Y, et al. Replacement of hystological findings: serum hyaluronic acid for fibrosis, high-sensitive C-reactive protein for necroinflamation in chronic viral hepatitis. International journal of clinical practice 2007 61 : 438 43.
48. Lu LG, Zeng MD, Mao YM, et al. Relationship between clinical and pathologic findings in patients with chronic liver diseases. World J Gastroenterol 2003 9 : 2796 800.
49. Imbert-Bismut F, Ratziu V, Pieroni L, Charlotte F, Benhamou Y, Polynard T MULTIVIRC Group. Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study. Lancet, The 2001 357 : 1069 75.
50. Rossi E, Adams L, Prins A, et al. Validation of the FibroTest biochemical markers score in assessing liver fibrosis in hepatitis C patients. Clin Chem 2003 49 : 450 4.
51. Halfon P, Bacq Y, De Muret A, et al. Comparison of test performance profile for blood tests of liver fibrosis in chronic hepatitis C. J Hepatol 2007 46 : 395 402.
52. Grigorescu M, Rusu M, Neculoiu D, et al. The FibroTest value in discriminating between insignificant and significant fibrosis in chronic hepatitis C patients. The Romanian experience. Journal of gastrointestinal and liver diseases 2007 16 : 31 7.
53. Halfon P, Bourliere M, Deydier R, et al. Independent prospective multicenter validation of biochemical markers (fibrotest-actitest) for the prediction of liver fibrosis and activity in patients with chronic hepatitis C: the fibropaca study. The American journal of gastroenterology 2006 101 : 547 55.
54. Sebastiani G, Vario A, Guido M, Albertini A. Performance of noninvasive markers for liver fibrosis is reduced in chronic hepatitis C with normal transaminases. J Viral Hepat 2008 15 : 212 8.
55. Poynard T, Munteanu M, Imbert-Bismut F, et al. Prospective analysis of discordant results between biochemical markers and biopsy in patients with chronic hepatitis C. Clin Chem 2004 50 : 1344 55.
56. Ngo Y, Munteanu M, Messous D, et al. A prospective analysis of the prognostic value of biomarkers (FibroTest) in patients with chronic hepatitis C. Clin Chem 2006 52 : 1887 96.
57. Myers RP, Ratziu V, Imbert-Bismut F, Charlotte F, Polynard T MULTIVIRC Group. Biochemical markers of liver fibrosis: a comparison with historical features in patients with chronic hepatitis C. The American journal of gastroenterology 2002 97 : 2419 25.
58. Myers RP, De Torres M, Imbert-Bismut F, Charlotte F, Poynard T MULTIVIRC Group. Biochemical markers of fibrosis in patients with chronic hepatitis C: a comparison with prothrombin time, platelet count, and age-platelet index. Dig Dis Sci 2003 48 : 146 53.
59. Myers RP, Benhamou Y, Imbert-Bismut F, et al. Serum biochemical markers accurately predict liver fibrosis in HIV and hepatitis C virus co-infected patients. AIDS 2003 17 : 721 5.
60. Zaman A, Rosen HR, Ingram K, Corless CL, Oh E, Smith K. Assessment of FIBROSpect II to detect hepatic fibrosis in chronic hepatitis C patients. The American journal of medicine 2007 120 : e9 14.
61. Christensen C, Bruden D, Livingston S, et al. Diagnostic accuracy of a fibrosis serum panel (FIBROSpect II) compared with Knodell and Ishak liver biopsy scores in chronic hepatitis C patients. J Viral Hepat 2006 13 : 652 8.
62. Patel K, Nelson DR, Rockey DC, et al. Correlation of FIBROSpect II with histologic and morphometric evaluation of liver fibrosis in chronic hepatitis C. Clinical gastroenterology and hepatology 2008 6 : 242 7.
63. Bourliere M, Peraranda G, Ouzan D, et al. Optimized stepwise combination algorithms of non-invasive liver fibrosis scores including Hepascore in hepatitis C virus patients. Aliment Pharmacol Ther 2008 28 : 458 67.
64. Maor Y, Calès P, Bashari D, et al. Improving estimation of liver fibrosis using combination and newer noninvasive biomarker scoring systems in hepatitis C-infected haemophilia patients. Haemophilia 2007 13 : 722 9.
65. Bantel H, Lügering A, Poremba C, et al. Caspase activation correlates with the degree of inflammatory liver injury in chronic hepatitis C virus infection. Hepatology 2001 1 (4 Pt 1) 758 67.
66. Bantel H, Lügering A, Heidemann J, et al. Detection of apoptotic caspase activation in sera from patients with chronic HCV infection is associated with fibrotic liver injury. Hepatology 2004 40 : 1078 87.
67. Zhang Q, Takahashi M, Noguchi Y, et al. Plasma amino acid profiles applied for diagnosis of advanced liver fibrosis in patients with chronic hepatitis C infection. Hepatology research 2006 34 : 170 7.
68. Maruyama S, Hirayama C, Horie Y, et al. Serum immunoglobulins in patients with chronic hepatitis C: a surrogate marker of disease severity and treatment outcome. Hepatogastroenterology 2007 54 : 493 8.
69. Lorenzo-Zúñiga V, Bartolí R, Masnou H, Montoliu S, Morillas RM, Planas R. Serum concentrations of insulin-like growth factor-I (igf-I) as a marker of liver fibrosis in patients with chronic hepatitis C. Dig Dis Sci 2007 52 : 3245 50.
70. Haydon GH, Jalan R, Ala-Korpela M, et al. Prediction of cirrhosis in patients with chronic hepatitis C infection by artificial neural network analysis of virus and clinical factors. J Viral Hepat 1998 5 : 255 64.
71. Piscaglia F, Cucchetti A, Benlloch S, et al. Prediction of significant fibrosis in hepatitis C virus infected liver transplant recipients by artificial neural network analysis of clinical factors. Eur J Gastroenterol Hepatol 2006 18 : 1255 61.
72. Cucchetti A, Vivarelli M, Heaton ND, et al. Artificial neural network is superior to MELD in predicting mortality of patients with end-stage liver disease. Gut 2007 56 : 253 8.
73. Gangadharan B, Antrobus R, Dwek RA, Zitzmann N. Novel serum biomarker candidates for liver fibrosis in hepatitis C patients. Clin Chem 2007 53 : 1792 9.
74. Mooney P, Hayes P, Smith K. The putative use of alpha-1-acid glycoprotein as a non-invasive marker of fibrosis. Biomed Chromatogr 2006 20 : 1351 8.
75. Mehta AS, Long RE, Comunale MA, et al. Increased levels of galactose-deficient anti-Gal immunoglobulin G in the sera of hepatitis C virus-infected individuals with fibrosis and cirrhosis. J Virol 2008 82 : 1259 70.
76. Suzman DL, McLaughlin M, Hu Z, et al. Identification of novel markers for liver fibrosis in HIV/hepatitis C virus coinfected individuals using genomics-based approach. AIDS 2008 22 : 1433 9.
77. Ferral H, Male R, Cardiel M, Munoz L, Quiroz y Ferrari F. Cirrhosis: diagnosis by liver surface analysis with high-frequency ultrasound. Gastrointestinal radiology 1992 17 : 74 8.
78. Simonovský V. The diagnosis of cirrhosis by high resolution ultrasound of the liver surface. The British journal of radiology 1999 72 : 29 34.
79. Lim AK, Taylor-Robinson SD, Patel N, et al. Hepatic vein transit times using a microbubble agent can predict disease severity non-invasively in patients with hepatitis C. Gut 2005 54 : 128 33.
80. Vyas K, Gala B, Sawant P, Das HS, Kulhalli PM, Mahajan SS. Assessment of portal hemodynamics by ultrasound color Doppler and laser Doppler velocimetry in liver cirrhosis. Indian J Gastroenterol 2002 21 : 176 8.
81. Weickert U, Buttmann A, Jakobs R, Schilling D, Eickhoff A, Riemann JF. Diagnosis of liver cirrhosis: a comparison of modified ultrasound and laparoscopy in 100 consecutive patients. J Clin Gastroenterol 2005 39 : 529 32.
82. Schneider AR, Teuber G, Kriener S, Caspary WF. Noninvasive assessment of liver steatosis, fibrosis and inflammation in chronic hepatitis C virus infection. Liver international 2005 25 : 1150 5.
83. Yamada H, Ebara M, Yamaguchi T, et al. A pilot approach for quantitative assessment of liver fibrosis using ultrasound: preliminary results in 79 cases. J Hepatol 2006 44 : 68 75.
84. Hirata M, Akbar SM, Horiike N, Onji M. Noninvasive diagnosis of the degree of hepatic fibrosis using ultrasonography in patients with chronic liver disease due to hepatitis C virus. Eur J Clin Invest 2001 31 : 528 35.
85. Lim AK, Patel N, Eckersley RJ, et al. Hepatic vein transit time of SonoVue: a comparative study with Levovist. Radiology 2006 240 : 130 5.
86. Abbattista T, Ridolfi F, Ciabattoni E, et al. Diagnosis of liver cirrhosis by transit-time analysis at contrast-enhanced ultrasonography. Radiol Med 2008 113 : 860 74.
87. Sandrin L, Fourquet B, Hasquenoph JM, et al. Transient elastography: a new noninvasive method for assessment of hepatic fibrosis. Ultrasound Med Biol 2003 29 : 1705 13.
88. Coco B, Oliveri F, Maina AM, et al. Transient elastography: a new surrogate marker of liver fibrosis influenced by major changes of transaminases. J Viral Hepat 2007 14 : 360 9.
89. Gómez-Domínguez E, Mendoza J, Rubio S, Moreno-Monteagudo JA, Gacías-Buey L, Moreno-Otero R. Transient elastography: a valid alternative to biopsy in patients with chronic liver disease. Aliment Pharmacol Ther 2006 24 : 513 8.
90. Ziol M, Handra-Luca A, Kettaneh A, et al. Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with chronic hepatitis C. Hepatology 2005 41 : 48 54.
91. Kettaneh A, Marcellin P, Douvin C, et al. Features associated with success rate and performance of FibroScan measurements for the diagnosis of cirrhosis in HCV patients: a prospective study of 935 patients. J Hepatol 2007 46 : 628 34.
92. Ogawa E, Furusyo N, Toyoda K, et al. Transient elastography for patients with chronic hepatitis B and C virus infection: Non-invasive, quantitative assessment of liver fibrosis. Hepatology research 2007 37 : 1002 10.
93. Takeda T, Yasuda T, Nakayama Y, et al. Usefulness of noninvasive transient elastography for assessment of liver fibrosis stage in chronic hepatitis C. World J Gastroenterol 2006 12 : 7768 73.
94. Ganne-Carrié N, Ziol M, de Ledinghen V, et al. Accuracy of liver stiffness measurement for the diagnosis of cirrhosis in patients with chronic liver diseases. Hepatology 2006 44 : 1511 7.
95. Vergara S, Macías J, Rivero A, et al. The use of transient elastometry for assessing liver fibrosis in patients with HIV and hepatitis C virus coinfection. Clin Infect Dis 2007 45 : 969 74.
96. Friedrich-Rust M, Ong MF, Herrmann E, et al. Real-time elastography for noninvasive assessment of liver fibrosis in chronic viral hepatitis. AJR Am J Roentgenol 2007 188 : 758 64.
97. Arena U, Vizzutti F, Abraldes JG, et al. Reliability of transient elastography for the diagnosis of advanced fibrosis in chronic hepatitis C. Gut 2008 57 : 1288 93.
98. Wong GL, Wong VW, Choi PC, et al. Assessment of fibrosis by transient elastography compared with liver biopsy and morphometry in chronic liver diseases. Clinical gastroenterology and hepatology 2008 6 : 1027 35.
99. Chang PE, Lui HF, Chau YP, et al. Prospective evaluation of transient elastography for the diagnosis of hepatic fibrosis in Asians: comparison with liver biopsy and aspartate transaminase platelet ratio index. Aliment Pharmacol Ther 2008 28 : 51 61.
100. Masaki N, Imamura M, Kikuchi Y, Oka S. Usefulness of elastometry in evaluating the extents of liver fibrosis in hemophiliacs coinfected with hepatitis C virus and human immunodeficiency virus. Hepatology research 2006 35 : 135 9.
101. Corradi F, Piscaglia F, Flori S, et al. Assessment of liver fibrosis in transplant recipients with recurrent HCV infection: Usefulness of transient elastography. Dig Liver Dis 2009 41 (3) 217 25.
102. Foucher J, Chanteloup E, Vergniol J, et al. Diagnosis of cirrhosis by transient elastography (FibroScan): a prospective study. Gut 2006 55 : 403 8.
103. Lupşor M, Badea R, Stefǎnescu H, et al. Analysis of histopathological changes that influence liver stiffness in chronic hepatitis C. Results from a cohort of 324 patients. Journal of gastrointestinal and liver diseases 2008 17 : 155 63.
104. Rouvière O, Yin M, Dresner MA, et al. MR elastography of the liver: preliminary results. Radiology 2006 240 : 440 8.
105. Huwart L, Peeters F, Sinkus R, et al. Liver fibrosis: non-invasive assessment with MR elastography. NMR Biomedicine 2006 19 : 173 9.
106. Huwart L, Sempoux C, Vicaut E, et al. Magnetic resonance elastography for the noninvasive staging of liver fibrosis. Gastroenterology 2008 135 : 32 40.
107. Huwart L, Sempoux C, Salameh N, et al. Liver fibrosis: noninvasive assessment with MR elastography versus aspartate aminotransferase-to-platelet ratio index. Radiology 2007 245 : 458 66.
108. Aguirre DA, Behling CA, Alpert E, Hassanein TI, Sirlin CB. Liver fibrosis: noninvasive diagnosis with double contrast material-enhanced MR imaging. Radiology 2006 239 : 425 37.
109. Lucidarme O, Baleston F, Cadi M, et al. Non-invasive detection of liver fibrosis: Is superparamagnetic iron oxide particle-enhanced MR imaging a contributive technique?. Eur Radiol 2003 13 : 467 74.
110. Lim AK, Patel N, Hamilton G, Hajnal JV, Goldin RD, Taylor-Robinson SD. The relationship of in vivo 31P MR spectroscopy to histology in chronic hepatitis C. Hepatology 2003 37 : 788 94.
111. Shiramizu B, Theodore D, Bassett R, et al. Correlation of single photon emission computed tomography parameters as a noninvasive alternative to liver biopsies in assessing liver involvement in the setting of HIV and hepatitis C virus coinfection: a multicenter trial of the Adult AIDS Clinical Trials Group. J Acquir Immune Defic Syndr 2003 33 : 329 35.
112. Groshar D, Slobodin G, Zuckerman E. Quantitation of liver and spleen uptake of (99m)Tc-phytate colloid using SPECT: detection of liver cirrhosis. The Journal of nuclear medicine 2002 43 : 312 7.
113. Hotta N, Ayada M, Okumura A, et al. Noninvasive assessment of liver disease - measurement of hepatic fibrosis using tissue strain imaging. Clin Imaging 2007 31 : 87 92.
114. Braden B, Faust D, Sarrazin U, et al. 13C-methacetin breath test as liver function test in patients with chronic hepatitis C virus infection. Aliment Pharmacol Ther 2005 21 : 179 85.
115. Klatt S, Taut C, Mayer D, Adler G, Beckh K. Evaluation of the 13C-methacetin breath test for quantitative liver function testing. Zeitschrift für Gastroenterologie 1997 35 : 609 14.
116. Goetze O, Selzner N, Fruehauf H, Fried M, Gerlach T, Mullhaupt B. 13C-methacetin breath test as a quantitative liver function test in patients with chronic hepatitis C infection: continuous automatic molecular correlation spectroscopy compared to isotopic ratio mass spectrometry. Aliment Pharmacol Ther 2007 26 : 305 11.
117. Lalazar G, Pappo O, Hershcovici T, et al. A continuous 13C methacetin breath test for noninvasive assessment of intrahepatic inflammation and fibrosis in patients with chronic HCV infection and normal ALT. J Viral Hepat 2008 15 : 716 28.
118. Dinesen L, Caspary WF, Chapman RW, Dietrich CF, Sarrazin C, Braden B. 13C-methacetin-breath test compared to also noninvasive biochemical blood tests in predicting hepatic fibrosis and cirrhosis in chronic hepatitis C. Digestive and liver disease 2008 40 : 743 8.
119. Schneider A, Caspary WF, Saich R, et al. 13C-methacetin breath test shortened: 2-point-measurements after 15 minutes reliably indicate the presence of liver cirrhosis. J Clin Gastroenterol 2007 41 : 33 7.
120. Schneider AR, Teuber G, Paul K, et al. Patient age is a strong independent predictor of 13C-aminopyrine breath test results: a comparative study with histology, duplex-Doppler and a laboratory index in patients with chronic hepatitis C virus infection. Clin Exp Pharmacol Physiol 2006 33 : 300 4.
121. Lackner C, Struber G, Liegl B, et al. Comparison and validation of simple noninvasive tests for prediction of fibrosis in chronic hepatitis C. Hepatology 2005 41 : 1376 82.
122. Kelleher TB, Afdhal N. Noninvasive assessment of liver fibrosis. Clin Liver Dis 2005 9 : 667 83.
123. Fabris C, Smirne C, Toniutto P, et al. Assessment of liver fibrosis progression in patients with chronic hepatitis C and normal alanine aminotransferase values: the role of AST to the platelet ratio index. Clin Biochem 2006 39 : 339 43.
124. Romera M, Corpas R, Romero Gómez M. Insulin resistance as a non-invasive method for the assessment of fibrosis in patients with hepatitis C: a comparative study of biochemical methods. Rev Esp Enferm Dig 2006 98 : 161 9.
125. Borroni G, Ceriani R, Cazzaniga M, et al. Comparison of simple tests for the non-invasive diagnosis of clinically silent cirrhosis in chronic hepatitis C. Aliment Pharmacol Ther 2006 24 : 797 804.
126. Bourliere M, Penaranda G, Renou C, et al. Validation and comparison of indexes for fibrosis and cirrhosis prediction in chronic hepatitis C patients: proposal for a pragmatic approach classification without liver biopsies. J Viral Hepat 2006 13 : 659 70.
127. Sebastiani G, Vario A, Guido M, et al. Stepwise combination algorithms of non-invasive markers to diagnose significant fibrosis in chronic hepatitis C. J Hepatol 2006 44 : 686 93.
128. Maor Y, Bashari D, Kenet G, et al. Non-invasive biomarkers of liver fibrosis in haemophilia patients with hepatitis C: can you avoid liver biopsy? Haemophilia 2006 12 : 372 9.
129. Leroy V, Hilleret MN, Sturm N, et al. Prospective comparison of six non-invasive scores for the diagnosis of liver fibrosis in chronic hepatitis C. J Hepatol 2007 46 : 775 82.
130. Oberti F, Valsesia E, Pilette C, et al. Noninvasive diagnosis of hepatic fibrosis or cirrhosis. Gastroenterology 1997 113 : 1609 16.
131. Aubé C, Winkfield B, Oberti F, et al. New Doppler ultrasound signs improve the non-invasive diagnosis of cirrhosis or severe liver fibrosis. Eur J Gastroenterol Hepatol 2004 16 : 743 51.
132. Testa R, Testa E, Giannini E, et al. Noninvasive ratio indexes to evaluate fibrosis staging in chronic hepatitis C: role of platelet count/spleen diameter ratio index. J Intern Med 2006 260 : 142 50.
133. Saito H, Tada S, Nakamoto N, et al. Efficacy of non-invasive elastometry on staging of hepatic fibrosis. Hepatology research 2004 29 : 97 103.
134. Castéra L, Vergniol J, Foucher J, et al. Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology 2005 128 : 343 50.
135. de Lédinghen V, Douvin C, Kettaneh A, et al. Diagnosis of hepatic fibrosis and cirrhosis by transient elastography in HIV/hepatitis C virus-coinfected patients. J Acquir Immune Defic Syndr 2006 41 : 175 9.
136. Shaheen AA, Myers RP. Diagnostic accuracy of the aspartate aminotransferase-to-platelet ratio index for the prediction of hepatitis C-related fibrosis: a systematic review. Hepatology 2007 46 : 912 21.
137. Shaheen AA, Myers RP. Systematic review and meta-analysis of the diagnostic accuracy of fibrosis marker panels in patients with HIV/hepatitis C coinfection. HIV clinical trials 2008 9 : 43 51.
138. Poynard T, Imbert-Bismut F, Munteanu M, et al. Overview of the diagnostic value of biochemical markers of liver fibrosis (FibroTest, HCV FibroSure) and necrosis (ActiTest) in patients with chronic hepatitis C. Comparative hepatology 2004 3 : 8.
139. Fontanges T, Bailly F, Trepo E, et al. Discordance between biochemical markers of liver activity and fibrosis (Actitest((R))-Fibrotest((R))) and liver biopsy in patients with chronic hepatitis C. Gastroentérol clin biol 2008.
140. Giannini E, Risso D, Botta F, et al. Validity and clinical utility of the aspartate aminotransferase-alanine aminotransferase ratio in assessing disease severity and prognosis in patients with hepatitis C virus-related chronic liver disease. Arch Intern Med 2003 163 : 218 24.
141. Colletta C, Smirne C, Fabris C, et al. Value of two noninvasive methods to detect progression of fibrosis among HCV carriers with normal aminotransferases. Hepatology 2005 42 : 838 45.
142. Yan G, Duan Y, Ruan L, Chao T, Yang Y. A study on the relationship between ultrasonographic score and clinical score (MELD, CPT) in cirrhosis. Hepatogastroenterology 2005 52 : 1329 33.
143. Iacobellis A, Mangia A, Leandro G, et al. External validation of biochemical indices for noninvasive evaluation of liver fibrosis in HCV chronic hepatitis. The American journal of gastroenterology 2005 100 : 868 73.
144. Calès P, Oberti F, Michalak S, et al. A novel panel of blood markers to assess the degree of liver fibrosis. Hepatology 2005 42 : 1373 81.
145. Nunes D, Fleming C, Offner G, et al. HIV infection does not affect the performance of noninvasive markers of fibrosis for the diagnosis of hepatitis C virus-related liver disease. J Acquir Immune Defic Syndr 2005 40 : 538 44.
146. Islam Sara, Antonsson L, Westin J, Lagging M. Cirrhosis in hepatitis C virus-infected patients can be excluded using an index of standard biochemical serum markers. Scand J Gastroenterol 2005 40 : 867 72.
147. Liu CH, Lin JW, Tsai FC, et al. Noninvasive tests for the prediction of significant hepatic fibrosis in hepatitis C virus carriers with persistently normal alanine aminotransferases. Liver international 2006 26 : 1087 94.
148. Parise ER, Oliveira AC, Figueiredo-Mendes C, et al. Noninvasive serum markers in the diagnosis of structural liver damage in chronic hepatitis C virus infection. Liver international 2006 26 : 1095 9.
149. Göbel T, Vorderwülbecke S, Hauck K, Fey H, Häussinger D, Erhardt A. New multi protein patterns differentiate liver fibrosis stages and hepatocellular carcinoma in chronic hepatitis C serum samples. World J Gastroenterol 2006 12 : 7604 12.
150. Wilson LE, Torbenson M, Astemborski J, et al. Progression of liver fibrosis among injection drug users with chronic hepatitis C. Hepatology 2006 43 : 788 95.
151. Sène D, Limal N, Messous D, et al. Biological markers of liver fibrosis and activity as non-invasive alternatives to liver biopsy in patients with chronic hepatitis C and associated mixed cryoglobulinemia vasculitis. Clin Biochem 2006 39 : 715 21.
152. Obrador BD, Prades MG, Gómez MV, et al. A predictive index for the diagnosis of cirrhosis in hepatitis C based on clinical, laboratory, and ultrasound findings. Eur J Gastroenterol Hepatol 2006 18 : 57 62.
153. Kawamoto M, Mizuguchi T, Katsuramaki T, et al. Assessment of liver fibrosis by a noninvasive method of transient elastography and biochemical markers. World J Gastroenterol 2006 12 : 4325 30.
154. Metwally MA, Zein CO, Zein NN. Predictors and noninvasive identification of severe liver fibrosis in patients with chronic hepatitis C. Dig Dis Sci 2007 52 : 582 8.